摘要
目的:观察国产盐酸吉西他滨(泽菲)配伍卡铂治疗非小细胞肺癌(NSCLC)的近期疗效及毒副作用。方法:初治NSCLC病例50例,以28d为1周期。采用第1、8天泽菲1.0g/m2,维泵静脉推注,第1天卡铂按AUC=5~6静脉滴注,连用两个周期后评价疗效及毒副作用。结果:全组50例,有效率为44.0%(22/50),主要毒副作用为胃肠反应(Ⅲ~Ⅳ级是6.0%)和血液学毒性,Ⅲ~Ⅳ级白细胞下降和血小板下降分别为10.0%和2.0%。结论:泽菲配伍卡铂治疗NSCLC有较好疗效,毒副作用小,患者耐受性好。
Objective: To observe the short term efficacy and toxicity reactions of domestic gemcitabine (ZEFEI) plus carboplatin (CBP) in the treatment of advanced non-small-cell lung cancer (NSCLC). Methods,50 cases of previously untreated patients with advanced NSCLC were given domestic gemeitabine (ZEFEI) on day 1.8 at a dose of 1.0g/m^2 and earboplatin at a dose of AUC=5-6 on day 1. The chemotherapy was repeated every 28 days with two cycles. Results:The response rate was 44. 0 (22/50), and the main toxicity reactions were nausea/vomiting (Ⅱ - Ⅳgrade 6.0%) and hematological toxicity, Ⅱ - Ⅳ grade leukopenia and thrombocytopenia were 10.0% and 2.0% respectively. Conclusion: The domestic gemcitabine (ZEFEI) plus carboplatin combination is a highly effective regimen for patients with advanced NSCLC, with a manageable toxicity.
出处
《陕西医学杂志》
CAS
北大核心
2006年第5期593-595,共3页
Shaanxi Medical Journal
关键词
诊断
药物疗法
嘧啶核苷类
卡铂
非小细胞肺癌
盐酸吉西他滨
Carcinoma, non-small-cell lung/diagnosis Carcinoma, non-small-cell lung/drug therapy Pyrimidine nucleosides/therapeutic use Carboplatin/therapeutic use